Grape King Bio Ltd (TPE:1707)
Taiwan · Delayed Price · Currency is TWD 120.00
0.00 (0.00%)
Mar 26, 2026, 1:30 PM CST
Grape King Bio Revenue
In the year 2025, Grape King Bio had annual revenue of 10.25B TWD, down -8.14%. Grape King Bio had revenue of 3.00B in the quarter ending December 31, 2025, a decrease of -4.84%.
Revenue
10.25B
Revenue Growth
-8.14%
P/S Ratio
1.73
Revenue / Employee
20.46M
Employees
501
Market Cap
17.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.25B | -908.40M | -8.14% |
| Dec 31, 2024 | 11.16B | 524.54M | 4.93% |
| Dec 31, 2023 | 10.64B | 244.23M | 2.35% |
| Dec 31, 2022 | 10.39B | 592.99M | 6.05% |
| Dec 31, 2021 | 9.80B | 630.05M | 6.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| YungShin Global Holding | 8.37B |
| Standard Chemical & Pharmaceutical | 7.02B |
| TTY Biopharm Company | 6.45B |
| Synmosa Biopharma | 6.11B |
| Formosa Laboratories | 4.85B |
| ScinoPharm Taiwan | 3.16B |
| Handa Pharmaceuticals | 1.62B |
| Center Laboratories | 1.52B |